UCB encouraged by novel lupus therapy
This article was originally published in Scrip
UCBhas presented proof-of-concept data for epratuzumab, a novel humanised anti-CD22 antibody, showing a reduction in disease activity and reduced reliance on corticosteroids in patients with severe systemic lupus (SLE), compared with placebo.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.